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INTRODUCTION
Neuroprotective and neurorestorative effects of glial cell 
 line-derived neurotrophic factor (GDNF) gene delivery have been 
demonstrated in phenotyical models of Parkinson’s disease (PD).1–4 
Partially encouraging clinical data have been obtained in clinical tri-
als using the closely related Neurturin (NTN) factor.5–9 Despite these 
studies, the precise mechanism of action of these neurotrophic fac-
tors in adult diseased brain still needs to be fully elucidated. Indeed, 
numerous studies have suggested that, in addition to enhanced 
dopaminergic neuron survival in phenotypical models of PD, poorly 
understood neurochemical effects on dopaminergic neurotransmis-
sion and dopamine biosynthesis10–13 are likely to participate to the 
clinical outcome of GDNF-based treatments. The latter vary with the 
time, dose, and mode of administration, further complicating the 
interpretation of the data. A recent study suggests that GDNF and 
Ret are dispensable for the maintenance of dopaminergic neurons.14 
However, in a lesional context, a clear GDNF-mediated protection of 
the dopaminergic connectivity has been demonstrated.1,4
Regardless of the mechanism of GDNF-mediated neuroprotective 
activity, side effects of long-term, high-dose or off-target delivery, 
such as aberrant sprouting, downregulation of tyrosine hydroxylase 
and loss of weight have been described.12,15–17 Altogether, it will be 
very interesting to have available clinically-relevant regulatable viral 
vectors in order (i) to provide a tool to dissect the diverse mecha-
nisms involved in the observed enhancement of the dopaminergic 
system and (ii) to optimize the outcome of clinical trials by modulat-
ing GDNF dose and period of administration.
The most widely used and best characterized regulatable system 
is the tetracycline-dependent (tet) system. Two versions exist: (i) the 
tetOFF system based on a fusion between the wild-type tet repres-
sor (tetR) and the activation domain of the HSV VP16 transcription 
factor18 and (ii) the tetON system in which the tetR sequence has 
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Preclinical and clinical data stress the importance of pharmacologically-controlling glial cell line-derived neurotrophic factor 
(GDNF) intracerebral administration to treat PD. The main challenge is finding a combination of a genetic switch and a drug 
which, when administered at a clinically-approved dose, reaches the brain in sufficient amounts to induce a therapeutic effect. 
We describe a highly-sensitive doxycycline-inducible adeno-associated virus (AAV) vector. This vector allowed for the first time a 
longitudinal analysis of inducible transgene expression in the brain using bioluminescence imaging. To evaluate the dose range 
of GDNF biological activity, the inducible AAV vector (8.0 × 109 viral genomes) was injected in the rat striatum at four delivery sites 
and increasing doxycycline doses administered orally. ERK/Akt signaling activation as well as tyrosine hydroxylase downregula-
tion, a consequence of long-term GDNF treatment, were induced at plasmatic doxycycline concentrations of 140 and 320 ng/ml 
respectively, which are known not to increase antibiotic-resistant microorganisms in patients. In these conditions, GDNF covered 
the majority of the striatum. No behavioral abnormalities or weight loss were observed. Motor asymmetry resulting from unilateral 
GDNF treatment only appeared with a 2.5-fold higher vector and a 13-fold higher inducer doses. Our data suggest that using the 
herein-described inducible AAV vector, biological effects of GDNF can be obtained in response to sub-antimicrobial doxycycline 
doses.
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been replaced by a mutant which reverses the phenotype from a 
tet-repressible to a tet-inducible system.19 Since long-term expo-
sure to antibiotics is undesirable, repeated punctual treatments 
using an inducible rather than a repressible system seems to be 
the most clinically-relevant option. The initial tetON system proved 
to be less sensitive to antibiotic inducers than the tetOFF system. 
However, new rtTA mutants selected through viral evolution in the 
presence of a low dose of doxycycline (Dox), have been isolated.20 In 
the brain, an additional concern is the low bioavailability of inducers 
which poorly pass the blood–brain barrier.21 Therefore, a sensitive 
transactivator is a prerequisite for applications in this organ.
Efficient ON/OFF kinetics with a single-cassette AAV-tetOFF sys-
tem in the rat brain has been demonstrated.22 Complete extinction 
of GDNF transgene expression required a plasmatic Dox concentra-
tion of ~300 ng/ml (100 mg Dox/kg diet).
We have conducted a similar effort to develop a single-cassette 
AAV-tetON system using the reverse tetracycline transactivator, 
rtTA-2S-M2 mutant23 mounted in a single autoregulatory AAV vec-
tor.11 In this study, Dox-dependent neurochemical effects as well 
as behavioral improvements have been obtained at a Dox dose of 
600 mg/l in drinking water11 (corresponding to a plasmatic concen-
tration of 5,400 ng /ml; unpublished data). Although a tight regula-
tion of GDNF levels in the brain, allowing to assess the reversibility 
of the observed biological effects has been demonstrated using this 
vector, its clinical applicability was hampered by the high amount of 
antibiotic required (higher than the plasmatic Dox doses measured 
in patients treated for infectious diseases24).
Other genetic switches have been successfully applied to modu-
late GDNF delivery.
Interestingly, the mifepristone (Mfp)-regulated Gene Switch 
which also uses an approved drug, was introduced in AAV vectors. 
Neuroprotective effects were demonstrated at a Mfp dose which, 
when adjusted using a FDA-approved rat to human conversion fac-
tor,25 was 2.5-fold lower than the dose administered for 7 days to 
patients for psychiatric indications in a randomized clinical trial in 
which no adverse effect was reported.26 This system, however, was 
tightly regulated only when used in a 2-vectors configuration.27
The rapamycin-regulated system, another dual-component sys-
tem also showed a tight regulation of GDNF transgene expression 
but the level of expression was low as compared to a constitutive 
vector.28 GDNF could also be regulated at the post-transcriptional 
level, using a fusion with a destabilizing domain.29,30
The herein described highly Dox-sensitive AAV inducible vector 
combines the advantages of the high Dox-sensitivity of the  rtTA-V16 
mutant20 and the tightness of the autoregulatory tet-inducible AAV 
vector.31 Therapeutically-relevant biological effects of GDNF were 
demonstrated in the rat brain, in response to orally administrated 
Dox at clinically-approved sub-antimicrobial doses. Indeed, the 
active plasmatic Dox concentration was below the levels measured 
in patients treated for inflammatory diseases of the skin32 and of the 
teeth surrounding tissue.33 Finally, these levels were proven not to 
increase the occurrence of Dox-resistant microorganisms and not to 
affect the intestinal flora.34,35
ReSUlTS
In vitro Dox dose-dependent transgene expression driven by a 
highly sensitive autoregulatory inducible AAV using the V16 rtTA 
mutant
Starting from a previously described autoregulatory tet-inducible 
AAV vector plasmid (pAC1-M2),31 we have replaced the rtTA-2S-M2 
mutant23 by the V16 mutant (3 mutations conferring improved Dox 
sensitivity)20 (Figure 1a). Hereafter, the new vector is referred to as 
pAC1-V16.
In order to compare the Dox sensitivity and overall induction 
amplitude of pAC1- M2 and pAC1-V16, two different transgenes 
were used luciferase (LUC) and human GDNF (hGDNF) cDNA.
The constructs were encapsidated into serotype 1 AAV capsids to 
generate rAAV2/1-tetON-V16 recombinant virus (hereafter referred 
as rAAV2/1-V16) and used at a multiplicity of infection of 1,000 viral 
genomes (vg) per cell to infect HEK-293T in the presence of adenovi-
rus type 5 (50 infectious units per ml). Cells were treated with increas-
ing Dox doses, ranging from 1 to 1,000 ng/ml. The amount of secreted 
hGDNF was measured in the medium of infected cells by enzyme-
linked immunosorbent assay (ELISA) (Figure  1b). The expression of 
the LUC reporter gene was measured in extracts from infected cells 
by luminometry (Figure  1c). The dose range of transgene expres-
sion was slightly different for hGDNF and LUC but both reflected the 
higher sensitivity of the V16 construct. Expression driven by rAAV2/1-
M2 was detectable from 100 ng/ml (GDNF) or 300 ng/ml (LUC) but 
resulted in significant levels of transgene expression only at the dose 
of 1,000 ng/ml whereas with the rAAV2/1-V16 vectors, expression was 
detectable from 1 ng/ml but significant expression levels were readily 
observed from 10 and 30 ng/ml for the hGDNF and LUC transgenes, 
respectively. Differences in protein stability and/or in the sensitivity of 
the measurement methods could account for the different detection 
thresholds observed with the GDNF and LUC transgene products. 
Furthermore, the amplitude of the induction was significantly higher 
with rAAV2/1-V16 (approximately 15 and 60 pg GDNF/ml for the M2 
and V16 vectors, respectively; Figure 1b).
Longitudinal analysis of transgene expression using in vivo 
bioluminescence imaging in the brain
In order to determine if the higher sensitivity of the V16 rtTA mutant 
to Dox can be confirmed in vivo in the brain, rAAV2/1-M2-LUC and 
rAAV2/1-V16-LUC (8.3 × 107 vg each) were injected in the striatum of 
adult mice which were subsequently fed with diet supplemented 
with Dox amounts ranging from 0.025 to 6 g/kg diet during 5 weeks 
(seven mice were injected for each group). First, brain protein 
extracts were analyzed using luminometry (n = 7). Figure 2a shows 
that, with the M2 mutant, no bioluminescent signal was detectable 
at any of the doses tested. In contrast, with the V16 mutant, the sig-
nal was significantly increased at the two highest doses: 1 and 6 g/
kg diet. In order to determine if the expression of the transgene was 
stable, we compared the intensity of the bioluminescent signal in 
mice continuously fed with Dox-supplemented (6 g/kg) or unsup-
plemented diet for 6 weeks (n = 5 for the no Dox group and n = 4 for 
Dox group) and 30 weeks (n = 7). Figure 2b shows that the relative 
light units per mg of proteins were similar at these two time points.
Thanks to the high sensitivity and efficiency of the rAAV2/1-V16 
vector, LUC reporter gene expression could be detected using in 
vivo bioluminescence imaging. Mice were stereotaxically-injected 
with rAAV2/1-V16-LUC and treated with a high Dox dose: 6 g/kg diet. 
Figure 2c shows the bioluminescent signal present in  Dox-treated 
(n = 4) but not in untreated (n = 7) mice, 4 weeks post-vector injec-
tion. Quantitative analysis of the signal revealed a significant dif-
ference between Dox-treated and untreated mice. Thanks to this 
technology, the kinetics of transgene expression upon Dox with-
drawal and readdition (ON/OFF/ON) could be performed without 
sacrificing animals at each time point (Figure 2d). We evaluated the 
delay after Dox withdrawal/addition necessary for full extinction/
induction of the vector. After feeding the mice (n = 4) for 1 month 
with Dox-supplemented food (Figure  2c,d), unsupplemented diet 
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was given for 7 weeks. Bioluminescence imaging was performed 
every second day starting 1 day post-Dox withdrawal. The signal 
was reduced from 3 days post-Dox removal but full extinction of the 
system required approximately 9 days. A second Dox treatment was 
implemented after 7 weeks of unsupplemented food. A biolumines-
cent signal was detected from 1 day after Dox administration but 
full induction of the system required approximately 5 days.
Measurements of Dox concentrations in rat’s plasma
In order to determine the threshold of clinically-acceptable doses 
in our experiments, rats (n = 8 per group) were given food con-
taining Dox at doses ranging from 0.025 to 1 g/kg. After 5 weeks 
of treatment, plasmatic Dox concentrations, measured using a 
previously described bioassay,21 were varying in function of the 
Dox dose in the rat diet (Figure 3). At the doses of 0.075 g and 0.2 
Dox/kg diet, the plasmatic Dox concentrations were 139 ± 40 and 
319 ± 50 ng/ml, respectively. These levels are respectively below 
and within the dose range found in patients treated for Rosacea 
(200–500 ng/ml),36 previously demonstrated not to increase the 
incidence of  Dox-resistant micro-organisms.34,37–39 Furthermore, 
these plasmatic Dox concentrations are one order of magnitude 
lower than those found in patients treated for bacterial infec-
tions (2.6–5.9 mg/ml).24
Dose-dependent hGDNF transgene expression in the rat striatum 
induced by Dox treatment
Recombinant AAV2/1-V16-hGDNF was injected in the right striatum 
at a total dose of 8.0 × 109 or 2.0 × 1010 vg. Rats were given food con-
taining Dox at doses ranging from 0.025 to 1 g/kg. Six weeks after 
vector injection, the rats (n = 6) were sacrificed and GDNF striatal tis-
sue concentration was measured using an ELISA (Figure 4a). In the 
untreated rats, the GDNF level was not significantly increased as com-
pared to the control rAAV2/1-V16-EGFP (enhanced green fluorescent 
protein)-injected rats. In the Dox-treated rats, a dose-dependent 
GDNF concentration was observed for both vector doses. Significant 
increases of GDNF concentration were observed from a Dox dose of 
0.2 and 0.025 g/kg, respectively for the low (8.0 × 109 vg) and the high 
(2.0 × 1010 vg) vector dose. Since it has been previously demonstrated 
that 200 pg/mg tissue of GDNF were sufficient to induce neuropro-
tective/neurorestorative effects of rAAV-mediated GDNF delivery,1,11,40 
we decided to focus on the low vector dose, which provided a GDNF 
concentration of 219.0 ± 46.6 pg/mg tissue at a Dox dose of 0.2 g/kg, 
for further characterizations.
Spatial distribution of GDNF in the striatum of Dox-treated rats
In order to optimize GDNF-mediated neuroprotection/neuroresto-
ration of dopaminergic neurons, a distribution of the neurotrophic 
Figure 1  Doxycycline-inducible adeno-associated virus (AAV) vectors. (a) AAV vectors plasmids used in this study. pAC1-M2-GDNF (previously 
described31) is an autoregulated tetracycline-inducible vector haboring a central bidirectional tetracycline-responsive promoter directing transcription 
of both the human GDNF cDNA and the M2 mutant of the reverse tetracycline transactivator (rtTA).23 In pAC1-M2-LUC, the hGDNF cDNA has been 
replaced by the LUC reporter gene (from pBI-GL, GenBank Accession No. U89935). In pAC1-V16 vector, the rtTA M2 mutant has been replaced by the 
V16 mutant.20 ITR, AAV inverted terminal repeat; pTetbidi, bidirectional tetracycline-responsive promoter promoter (from pBI-GL, GenBank Accession 
No. U89935); rtTA-M2, reverse tetracycline transactivator mutant; rtTA-V16, reverse tetracycline transactivator mutant; bidirectional arrow, bidirectional 
SV40 polyadenylation site. (b,c) In vitro comparison of Dox sensitivity. HEK-293T cells were coinfected with pAC1 constructs encapsidated into serotype 
1 AAV capsids and adenovirus type 5 helper. Cells were treated with Dox at increasing doses for 48 hours. For glial cell line-derived neurotrophic factor 
(GDNF) vectors, the medium was harvested 48 hours postinfection and analyzed using an enzyme-linked immunosorbent assay. For LUC vectors, cells 
were lysed and protein extracts analyzed using a luminometer. RLU, relative light units. *P < 0.05; **P < 0.01; ***P < 0.001 versus untreated cells.
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factor covering the majority of the putaminal dopaminergic fibers 
is required.8 Therefore, the spatial distribution of GDNF protein after 
injection of rAAV2/1-V16-hGDNF at the low vector dose was exam-
ined (four rats per group were analyzed). At Dox doses of 0.075, 0.2, 
and 1 g/kg, 70, 75, and 90% of the striatum was respectively labeled. 
Figure 4b illustrates the antero-posterior distribution of the stain-
ing in a representative treated with 0.2 g Dox/kg diet. It shows that 
GDNF could be evidenced throughout the striatum over at least 
a 2.4 mm range (Figure  4b). In contrast, at the dose of 0.025 g/kg 
as well as in untreated rats, the GDNF staining harbored a low but 
detectable intensity covering 30% of the striatum. The quantifi-
cation of the stainings reveals that at the two highest Dox doses 
(0.2 and 1 g/kg diet), the GDNF immunoreactivity was significantly 
increased as compared with the untreated group and the EGFP con-
trol group (Figure  4c). In contrast, for the two lower doses (0.075 
and 0.025 g Dox/kg diet), it was not significantly different from the 
untreated and control groups. These data are in accordance with 
the results of the ELISA (Figure 4a).
Although the two needle tracts, visible on some of the rats were 
confirmed to be located at the expected coordinates in the stria-
tum, a strong GDNF staining was observed in a region located out-
side the striatum beyond the borders between the striatum and the 
cortex, more specifically at the ventro-lateral side (see Figure  4b). 
Such a strong tropism of rAAV2/1 vectors for neurons located at dis-
tance from the injected site, presumably in the external capsule, has 
already been previously reported.31
Dox dose range of GDNF-mediated induction of ERK  pathway-
dependent S6 ribosomial protein phosphorylation on Ser-235 and 
Ser-236
We then sought to determine at which Dox dose a significant 
induction of GDNF-mediated biological effects could be observed. 
Therefore, we evaluated the amounts of Ser-235 and Ser-236 
Figure 2 Ex vivo and in vivo evaluation of luciferase expression in the striatum of recombinant adeno-associated virus (rAAV)2/1-tetON-injected 
mice. rAAV2/1-LUC vector (8.3 × 107 vg) was stereotaxically-injected in the striatum of CD1 mice (n = 7). (a) Mice were stereotaxically-injected with 
rAAV2/1-M2-LUC (circles) or rAAV2/1-V16-LUC (squares) and treated with increasing Dox doses starting immediately after injection until the end of 
the experiment (n = 7 for each Dox dose and for the two vectors). Five weeks postinjection, bioluminescence was evaluated in striatal protein extracts. 
***P < 0.001 versus untreated mice. (b) Mice were stereotaxically-injected with rAAV2/1-V16-LUC and treated with Dox at a dose of 6 g/kg diet starting 
immediately after injection until the end of the experiment. Six weeks (n = 5 for no Dox and n = 4 for Dox) or 30 weeks (n = 7 for no Dox and Dox) 
postinjection, bioluminescence was evaluated in striatal extracts. *P < 0.05; **P < 0.01 versus untreated mice. (c) Mice stereotaxically-injected with 
rAAV2/1-V16-LUC were continuously treated with Dox at a dose of 6 g/kg diet starting immediately after injection (n = 7 and n = 4 for no Dox and Dox 
groups, respectively). Bioluminscence imaging was performed at 5 weeks postinjection. *P < 0.05 using a Student t-test. (d) After 5 weeks of treatment 
with Dox diet (6 g/kg), mice (n = 4) were fed with unsupplemented food (Dox withdrawal) and bioluminescence imaging was performed every 2 days, 
starting 1 day post-Dox withdrawal. After an additional period of 5 weeks, the mice received Dox diet (6 g/kg) and bioluminescence imaging was 
performed at the additional indicated days until day 34. RLU, relative light units; cpm/cm2 counts per minute per cm2.
0 0.025
rAAV2/1-M2-Luc8.0 × 10
6
4.0 × 106
800
600
400
cp
m
/c
m
2
200
0
800
*
600
400
cp
m
/c
m
2
200
0
0 1 3 5 0
Days
Dox administration
Five weeks
Dox withdrawal
1 3 5 9 13 19 26 347 9 11No Dox Dox
3.0 × 106
2.0 × 106
1.0 × 106
0
6.0 × 106
4.0 × 106
R
LU
 (U
.
A.
)/m
g o
f to
tal
 pr
ote
ins
R
LU
/m
g 
of
 to
ta
l p
ro
te
in
s
2.0 × 106
0
rAAV2/1-V16-Luc
[Dox] (g/kg diet)
6 30
Weeks postinjection of rAAV
ns
No Dox
Dox
No Dox Dox
**
*
***
***
0.2 1 6
a
c d
b
Figure 3 Plasmatic Dox concentrations in function of the Dox dose in the 
rats diet. Rats (n = 8) were treated with increasing Dox doses for 5 weeks. 
Plasma was harvested as described in Material and Methods and Dox 
concentrations evaluated using a previously described cell-based assay.21
1,500
1,000
[D
ox
] in
 th
e p
las
ma
 (n
g/m
l)
500
0
0 0.025 0.075
[Dox] (g/kg diet)
ns
ns
***
***
0 2
3 
± 
61
13
9 
± 
40 31
9 
± 
50
96
0 
± 
24
5
0.2 1
5Sensitive AAV vector for inducible GDNF delivery.
A Chtarto et al.
Molecular Therapy — Methods & Clinical Development (2016) 16027Official journal of the American Society of Gene & Cell Therapy
phosphorylated S6 ribosomal protein (p-S6) in dopaminergic neu-
rons as an indicator of GDNF-induced ERK/Akt signaling cascade.41
Recombinant AAV2/1-V16-hGDNF, was injected in the right stria-
tum at a dose of 8.0 × 109 vg as described above (n = 6 rats per Dox 
dose). Peroxidase staining of midbrain sections using antibodies 
against p-S6 allows to evidence unilateral activation of the ERK sig-
naling pathway in the substantia nigra of the injected hemisphere.30 
A Dox dose-dependent increase of p-S6 staining was observed. This 
increase reached significance at Dox doses of 0.075 g /kg diet and 
higher (Figure 5).
Dox dose range of GDNF-induced downregulation of tyrosine 
hydroxylase
We next evaluated the effect of GDNF transgene expression induced 
by Dox on TH protein level in the striatum using immunohistochem-
istry (Figure 6). A densitometric analysis of TH labeling in the striatum 
revealed a significant downregulation at doses of 0.2 and 1 g Dox/kg 
diet as compared to the untreated (“no Dox”) and to the EGFP control 
groups (n = 6 rats per Dox dose). Thus, the minimal Dox dose pro-
voking TH downregulation was approximately threefold higher than 
the minimal dose inducing S6 phosphorylation. The optical densities 
in the “no Dox”, 0.025 and 0.075g Dox /kg diet experimental groups 
were not significantly different from the EGFP group.
Absence of glial cells activation
When delivered into the muscle, the rtTA transactivator elicits a strong 
immune response leading to the elimination of transduced cells.42 The 
long-term stability of transgene expression mediated by rAAV2/1-V16 
(see Figure  2) suggests the absence of a strong cellular immune 
response. To determine if a mild inflammatory response could never-
theless take place, we examined the expression level of astrocytic (glial 
fibrillary acidic protein (GFAP)) and microglial (IbaI) markers which 
are upregulated when these cells are activated. Sections from rats 
injected with rAAV2/1-V16-hGDNF (8.0 × 109) vg and fed with Dox diet 
or unsupplemented food were labeled with anti-GFAP and anti-IbaI 
antibodies (two rats per group). The stainings were of similar intensity 
and the glial cells morphology were similar in the injected and intact 
sides, for all Dox doses tested (see Figure 7d, panels e versus f (IbaI) and 
Figure 7j, panels k versus l (GFAP) for a representative example of a rat 
treated with 1g Dox/kg diet), indicating that the vector did not induce 
any detectable activation of glial cells 9 weeks after vector injection. 
In addition, the staining were also similar in rats fed with unsupple-
mented food (Figure 7a–c and g–i) as compared to rats fed with a high 
Dox dose (1 g/kg diet; Figure 7d–f and j–l) expressing a high level of 
GDNF (see Figure 4) and thus presumably of rtTA-V16.
Dox dose range of GDNF-mediated motor abnormalities
Contralateral amphetamine-induced rotations were reported 
after unilateral injection of AAV vectors constitutively expressing 
GDNF in healthy rats.1 We first analyzed the motor behavior after 
intrastriatal injection of rAAV2/1-V16-hGDNF at a vector dose of 
8.0 × 109 vg, which induced ERK signaling at a Dox dose of 0.075 g/
kg diet (see above). No significant difference in the number of 
 amphetamine-induced rotations was observed between the EGFP 
group and all the Dox-treated groups (from 0.025 to 1 g Dox/kg diet; 
n = 8 rats per group) (Figure 8a).
Figure 4 Striatal glial cell line-derived neurotrophic factor (GDNF) expression after doxycycline induction. (a) Quantification of GDNF tissue levels was 
performed 6 weeks after injection of 8.0 × 109 or 2.0 × 1010 vg of recombinant adeno-associated virus (rAAV)2/1-V16-hGDNF in the right striatum. Rats 
were continuously fed with Dox supplemented diet containing 0.025, 0.075, 0.2, or 1 g Dox/kg or with unsupplemented food. Results are expressed as 
mean of GDNF concentration in striatal protein extracts; n = 6 rats/Dox dose for low dose of vector and n = 8 for high dose of vector (#P < 0.05; ##P < 0.001; 
###P < 0.001 versus the enhanced green fluorescent protein group). (b) Spatial distribution of the GDNF transgene product. GDNF immunostaining was 
performed 9 weeks following injection of 8.0 × 109 vg of rAAV2/1-V16-hGDNF in the right striatum. Rats were continuously fed with Dox-supplemented 
diet containing 0.025, 0.075, 0.2, or 1 gr of Dox/ kg or with unsupplemeted food. The figure illustrates an example of GDNF immunoreactivity in striatum 
of a rat treated with 0.2 g Dox /kg of diet. Scale bar: 2 mm. (c) The GDNF labeling was quantified by multiplying the mean of grayscale by the stained 
area on four slices at the level of injection. n = 4 rats/Dox dose. ***P < 0.001 versus the no Dox group).
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In order to determine the safety limits of rAAV2/1-V16-GDNF, a 
2.5-fold higher vector dose was injected in four deposits at the same 
antero-posterior level (in order to obtain a high local GDNF tissue 
concentration) (n = 8 rats per group). Amphetamine-induced rota-
tions significantly different from the EGFP group appeared between 
20 and 50 minutes post-amphetamine injection at a dose of 1 g Dox/
kg diet. This perturbation of the motor behavior thus only appeared 
at a 2.5-fold higher vector dose combined with a 13-fold higher Dox 
dose than the minimal dose inducing ERK/Akt signaling (Figure 8b).
Absence of weight loss
Important weight loss was described when delivering AAV vectors 
constitutively expressing GDNF, in the rat16 and monkey substantia 
nigra.17 Since we previously demonstrated a low level of anterograde 
transport of the transgene product in the substantia nigra pars 
reticulata using the AAV2/1- M2 vector,11,43 we compared the weight 
curves of rAAV2/1-V16- GDNF-treated rats to  rAAV2/1-V16-EGFP at 
both vector doses (8.0 × 109 and 2.0 × 1010 vg; n = 8 rats per group). 
In accordance with previous studies,17,22 we did not observe any 
significant reduction of the weight when the vectors were injected 
in the striatum and furthermore the weight gain was not different 
between the GDNF-treated and control rats (Figure 8c,d).
DISCUSSION
We describe a single autoregulatory AAV vector using a mutant of 
the reverse tetracycline transactivator selected for its high sensi-
tivity to Dox,20 which mediates therapeutically relevant biological 
effects of GDNF in response to sub-antimicrobial Dox doses. These 
Figure 5 Nigral pS6 immunoreactivity after doxycycline induction. Serine 235/236 phosphorylated S6 ribosomal protein (p-S6) immunostaining was 
performed 9 weeks following intra-striatal injection of 8.0 × 109 vg of recombinant adeno-associated virus (rAAV)2/1-V16-hGDNF. Rats were fed with Dox-
supplemented diet containing 0.025, 0.075, 0.2, or 1 g of Dox/kg or with unsupplemented food during 9 weeks. (a,b) Example of p-S6 immunoreactivity in 
substantia nigra pars compacta (SNc) of a rat treated by 0.2 g Dox /kg of diet (a) and an untreated rat (b). Scale bar: 2 mm (c) The p-S6 immunoreactivity is 
reported as the mean of the optical densities multiplied by the stained area measured on two to three slices at the level of SNc. n = 6 rats/Dox dose. **P < 0.01, 
***; P < 0.001 versus no Dox group and #P < 0.05, ###P < 0.001 versus enhanced green fluorescent protein group. GDNF, glial cell line-derived neurotrophic factor.
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Figure 6 Tyrosine hydroxylase (TH) immunoreactivity after doxycycline induction. TH immunostaining was performed 9 weeks following intra-striatal 
injection of 8.0 × 109 vg of AAV2/1-V16-hGDNF. (a–d) Representative pictures of TH immunoreactivity of rats fed with unsupplemented food (a) or  Dox-
supplemented diet containing 0.025 (b), 0.075 (c), 0.2 (d), or 1 gr of Dox/kg during 9 weeks. Scale bar: 2 mm (e) Values represent percentage of decrease 
of TH immunoreactivity relative to the striatum contralateral to the viral injection. n = 6 rats/Dox dose. ***P < 0.001 versus no Dox group and ##P < 0.01 
versus enhanced green fluorescent protein group). GDNF, glial cell line-derived neurotrophic factor.
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data were obtained using a clinically-relevant protocol. Indeed, the 
rAAV vector was stereotaxically-infused at four delivery sites along 
two needle tracts at a dose of 8.0 × 109 vg/striatum (3.0 × 108 vg/
mm3), i.e., fourfold-higher than that used in the rAAV2-NTN clini-
cal trial which was demonstrated to be safe5,6,44,45 and similar to the 
highest dose approved for the ongoing rAAV2-GDNF clinical trial 
(https://clinicaltrials.gov/ct2/show/NCT01621581).
Dox at a dose of 200 mg per day, combined with other antibiot-
ics, is recommended for the treatment of patients with brucellosis, a 
bacterial infection.46 However, long-term treatment raises concerns 
both in terms of adverse effects for the treated patient (phototoxic-
ity, hepatotoxicity, bone toxicity, etc.) and epidemiologically, in terms 
of increased incidence of Dox-resistant microorganisms.47 In con-
trast, Dox, administrated at lower sub-antimicrobial doses elicit no or 
very mild adverse effects and has been approved for the treatment 
of benign inflammatory diseases. In particular, it has been demon-
strated, in phase 3 clinical trials involving several hundreds of patients 
with Rosacea, a skin disease, that a dose of 40 mg Dox has anti-inflam-
matory effects, while not increasing the number of Dox-resistant 
microorganisms in fecal and vaginal samples.32,36,39,48 Similarly, in the 
treatment of periodontitis with 20 mg Dox daily administration, no 
changes in antibiotic susceptibility have been reported.37
Since the metabolization of antibiotics is different in rodents 
and human, the orally administrated Dox dose might not provide a 
reliable basis for comparison. It is thus preferable, to use plasmatic 
concentrations for inter-species comparisons. In patients treated 
for bacterial infections (200 mg per day), the peak plasmatic con-
centration ranges from 2,600 to 5,900 ng/ml24 whereas in patients 
treated for Rosacea (40 mg per day), it was found to vary between 
200–500 ng/ml36 and in patients with periodontitis treated with 
20 mg Dox daily for long periods, it reached 400 ng/ml.33
In our previous studies using the tetracycline-inducible 
 rAAV2/1-M2 vector, a Dox dose of 600 mg/l in drinking water was 
necessary to obtain vector-mediated biological effects of hGDNF, 
including TH downregulation in healthy rats31 and partial behavioral 
recovery in the partial 6-hydroxydopamine PD rat model.11 In these 
conditions, the plasmatic Dox concentration reached 5,378 ng/ml 
(L. Tenenbaum and A.T. Das, data not shown), thus similar to the 
highest level in patients treated for bacterial infections and 13-fold 
higher than the levels found in clinical trials for Rosacea.
In contrast, using the herein described rAAV2/1-V16-hGDNF, 
induction of ribosomal S6 protein phosphorylation on Ser-235/236 
(p-S6) (a downstream product of mTOR and ERK signaling path-
ways mediated by GDNF41,49) were induced at a plasmatic Dox 
Figure 7 Absence of astrocytic and microglial activation upon long-term recombinant adeno-associated virus (rAAV)2/1-V16 induction. Rats injected 
with rAAV2/1-V16-hGDNF (8.0 × 109 vg) and treated with Dox diet at a concentration of 1 g/kg (d–f,j–l) or unsupplemented food (a–c,g–i) for 9 weeks. 
Brain sections were labeled with anti-IbaI (panels a–f) and anti-glial fibrillary acidic protein (panels g–l) antibodies. Pictures show the stainings of the 
injected (c,f,i,l) and intact (b,e,h,k) sides. Arrows indicate cells with the typical morphology of resting microglia (b–f) and astrocytes (h–l). Sections 
from two rats were labeled for each group. Scale bar: 500 µm for 2× magnification and 10 µm for 40× magnification. GDNF, glial cell line-derived 
neurotrophic factor.
IbaI
GFAP
Intact side Injected side
Intact side
D
ox
N
o 
D
ox
D
ox
N
o 
D
ox
Injected side
a b c
d e f
g h i
j k l
8Sensitive AAV vector for inducible GDNF delivery.
A Chtarto et al.
Molecular Therapy — Methods & Clinical Development (2016) 16027 Official journal of the American Society of Gene & Cell Therapy
concentration of 140 ng/ml, thus lower than the levels measured 
in the plasma of patients treated for Rosacea. The neuroprotec-
tive/neurorestaurative effects of rAAV2/1-V16-hGDNF remain to be 
demonstrated in a PD model. However, in a previous study using 
GDNF gene transfer in the intrastriatal 6-hydroxydopamine PD 
model,30 a reduction of the motor symptoms, evaluated using three 
different behavioral tests was associated to a 1.5-fold increase of the 
p-S6 immunolabeling in the substantia nigra. In the present study, 
a similar densitometric quantification revealed a four- to fivefold 
increased p-S6 labeling in rats treated with 0.075 g Dox/kg diet. Our 
data strongly suggest that rAAV2/1-V16-hGDNF can mediate neuro-
protection at this dose, corresponding to a plasmatic dose of 140 ng 
Dox/ml.
Several other systems have been proposed to regulate GDNF 
administration in the brain.
A single rAAV2/5-TetOFF vector administered at a very high titer 
(7.3 × 1013 vg/ml) was shown to deliver high amounts of GDNF in 
the striatum in the absence of Dox, provoking TH downregulation 
as well as a reduction of weight gain.22 A Dox dose of 100 mg/kg diet 
was sufficient to fully extinguish GDNF expression.
The mifepristone-responsive gene switch system27 has been dem-
onstrated to provide neurorestoration after a  6-hydroxydopamine 
partial lesion in response to an inducer dose of 20 mg/kg. This dose, 
when corrected for the rat-human conversion factor using the body 
surface area,25 was lower than the mifepristone dose administered 
for 7 days to bi-polar patients in a randomized clinical trial in which 
no adverse effect was reported. However, with this system, two 
separate vectors with a precisely adjusted ratio were necessary to 
obtain a tight regulation. Interestingly, these authors have demon-
strated that pulses of GDNF administration, not provoking TH down-
regulation, were as efficient as a continuous treatment in terms of 
neurorestauration.40 Therefore, repeated short-term expression of 
the therapeutic transgene might constitute the treatment of choice 
for slowly degenerative diseases.
Another dual transcriptionally-regulated vector system is the 
rapamycin-inducible cassette.28 This regulatable system was how-
ever far less efficient than a constitutive promoter and did not allow 
to cover a sufficient proportion of the striatum, despite very high 
vector doses.
An alternative interesting system consists in regulating GDNF at 
the protein level by using a fusion with the destabilizing domain 
(DD) of Escherichia coli dihydrofolate reductase.29,30 In this system, 
the antibiotic trimethoprim stabilizes the DD-domain allowing to 
secrete functional GDNF. Trimethoprim is used to treat urinary infec-
tions at a dose of 200 mg/day (approximately 30 mg/kg/day). The 
concentration necessary to induce the stabilization of the GDNF-DD 
in rats was within the range of antimicrobial activity (0.5 mg/ml in 
drinking water, i.e., approximately 50 mg/kg/day).
For all these regulatable systems, an additional challenge is to 
obtain therapeutical effects in the ON state, using an acceptable 
vector dose within the safety and tolerability limits, while keeping a 
negligible transgene product activity in the OFF state.
We have tested two doses of rAAV2/1-V16 vector: 8.0 × 109 vg 
(moderate dose) and 2.0 × 1010 vg (high dose) per rat striatum 
(approximately 25 mm3) corresponding to 3.2 × 108 and 8.0 × 108 vg/
mm3, respectively. When extrapolated to the volume of the human 
Figure 8 High-dose intrastriatal recombinant adeno-associated virus (rAAV)2/1-V16-hGDNF injection mediates doxycycline-dependent  amphetamine-
induced behavioral asymmetry but no reduction of weight gain. Recombinant AAV2/1-V16-hGDNF or rAAV2/1-V16-enhanced green fluorescent protein 
(EGFP) viral suspensions were stereotaxically-injected in the right striatum at two different doses: 8.0 × 109 (a,c) and 2.5 × 1010 vg (b,d). Animals (n = 8 
per group) were treated with Dox at doses of 0.025, 0.075. 0.2, and 1 g/kg diet or untreated (no Dox). (a,b) Eight weeks later, amphetamine (2.5 mg/
kg) was injected intraperitoneally and rotational behaviour was assessed during 60 minutes and recorded every 10 minutes. The values indicate the 
net number of full contralateral turns (counter-clockwise minus clockwise) per 10 minutes. N = 8 for all groups. #P < 0.05; ##P < 0.01 versus EGFP group; 
*P < 0.05 versus no Dox group. (c,d) The rats’ weight was recorded at the day of vector injection and 80 days after starting the Dox treatment. Data are 
expressed relative the EGFP group which is set at 100%. The difference between glial cell line-derived neurotrophic factor (GDNF) and EGFP-injected 
rat’s weight was not significant (n = 8 per group).
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putamen (3,500 mm3), these vector doses correspond respectively 
to 4-fold and 10-fold more than the amount of vg that was admin-
istered in the Phase II CERE-120 clinical trial (2.7 × 1011 rAAV2-NTN 
vg/hemisphere, i.e., 7.7 × 107 vg/mm3). It should be noted that at the 
moderate vector dose, a small amount of GDNF was evidenced in 
the untreated (no Dox) group (see Figure 3). This leakiness of the 
system, however, was not sufficient to significantly induce ERK sig-
naling, nor to downregulate TH.
Despite the distribution of the vector delivery in the central part 
of the striatum, an intense GDNF staining was observed outside the 
striatum, particularly in a ventro-lateral area located beyond the 
 striatal-cortical border. This accumulation of GDNF at distance from 
the injection area could result either from an unequal diffusion of viral 
particles or from heterogeneous diffusion of GDNF. Since a similar 
tropism of rAAV2/1 vectors for neurons located at distance from the 
injected site, in a similar area, has already been previously observed 
using an intracellular transgene product (EGFP) and a single needle 
tract (see reference 32, Figure 5), it is likely that the diffusion and/or 
tropism of rAAV2/1 viral particles rather than that of GDNF, explain 
this uneven transduction pattern. In order to reduce the risk of off-
target GDNF effects, other AAV serotypes could possibly be used.
Induction of ERK signaling promoting neuronal survival appeared 
at a Dox concentration of 140 ng/ml plasma (Figure 7), thus lower 
than that found in patients treated with the FDA-approved dose 
for anti-inflammatory treatments. TH downregulation, previously 
described as a feed-back effect of long-term GDNF treatment in rats, 
appeared at a dose of 320 ng/ml plasma. It should be noted how-
ever that this undesired effect of GDNF has never been described in 
non-human primates, questioning its relevance. Behavioral abnor-
malities only started to appear with a 2.5-fold higher vector dose 
and at a dose of 960 ng Dox/ml plasma which, due to the risk of anti-
biotic resistance, will not possibly be administered to patients for 
safety reasons. Finally, no significant reduction of weight gain was 
observed even at the highest vector and Dox doses.
Another limiting factor of available regulatable systems is the 
immune response to proteic components. Intramuscular injections 
of a previous version of the rtTA transactivator have been repeatedly 
shown to induce a strong immune response resulting in the rejection 
of transduced cells in macaques42,50 but not in mice.51 Replacement 
of the minimal VP16 activation domain of the rtTA by a humanized 
moiety while retaining the tetR bacterial DNA-binding domain did 
not reduce immune rejection.51 In contrast, by fusing to the rtTA cod-
ing sequence a portion of the Epstein-Barr virus nuclear antigen-1 
protein which promotes immune evasion,52 a significant reduction of 
the rtTA immunogenicity has been demonstrated in vivo as well as 
in an in vitro assay for human antigen presentation.53 On the other 
hand, the rtTA transactivator was not immunogenic when injected in 
the macaque retina54 questioning the relevance of this issue for gene 
therapy in immunologically-privileged organs such as the eye and 
the brain. Accordingly, our data showing that  long-term overexpres-
sion of rtTA-V16 does not lead to the abolition of transgene expres-
sion suggesting that no cellular immune response eliminating the 
transduced cells has occurred. Furthermore, no activation of glial cells 
has been observed, suggesting that no local inflammatory response 
to the rtTA-V16 protein occurred. The mifepristone gene switch con-
sists in a humanized transactivation domain but contains a prokary-
otic DNA binding domain (Gal 4).27 Successful repeated induction of 
transgene expression at the same level, suggests that there was no 
cellular immune response in the rat brain. Similarly, the DHFR desta-
bilizing domain used to regulate GDNF protein by trimethoprim30 is 
originating from E. coli and thus also potentially immunogenic.
In conclusion, the safe therapeutic window of our novel 
 doxycycline-inducible AAV vector, in terms of number of vector 
genomes and Dox dose range is wide: at least between 140 ng/
ml plasma (efficiency threshold) and 1 mg/ml plasma (antimicro-
bial threshold) for Dox and between 3 × 108 vg/mm3 (efficiency 
threshold) and 8 × 108 vg/mm3 (vector dose provoking motor 
symptoms at high Dox dose). Hence, our data suggests that a 
 pharmacologically-regulated protocol for GDNF-mediated neuro-
protective treatment of Parkinson’s disease could be established by 
combining the administration of rAAV2/1-V16-hGDNF in a single 
stereotaxic neurosurgery with oral administration of Dox at a dose 
which is safe for both the patients and the environment. Whether 
neuroprotective/neurorestaurative effects of rAAV2/1-V16-hGDNF 
can be obtained at similar Dox doses remains to be demonstrated. It 
also remains to be determined in relevant animal or cellular models 
whether immune response against the rtTA-V16 transactivator will 
raise a safety concern.
MATeRIAlS AND MeTHODS
Plasmids
The pAC1-M2 plasmid comprising AAV ITRs bracketing the bidirectional tet-
racycline-responsive cassette expressing both rtTAM2 and EGFP has been 
previously described31 (Figure 1a). To obtain pAC1-V16, the rtTA transactiva-
tor present in pAC1 (ref. 55) has been replaced by rtTAV16, a rtTA mutant 
deriving from rtTA-2S-S2 (ref. 23) and harboring three additional muta-
tions (V9I, F67S, and R171X), selected in the presence of a low Dox dose20 
(Figure 1a). The human GDNF (hGDNF) and the luciferase cDNA, respectively, 
have been introduced in this autoregulatory tetracycline inducible vector at 
the 5’ end of the bi-directional tetracycline promoter (pTetbidi).
Cell line
The HEK-293T Human Embryonic Kidney cell line was obtained from Q-One 
Biotech (Glasgow, UK). Cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Life Technologies, Merelbeke, Belgium) supplemented 
with 10% fetal calf serum (Sigma-Aldrich, Diegem, Belgium).
Viral production
To produce recombinant AAV2/1 viral stocks, HEK-293T cells (5.0 × 106 cells 
per 10 cm plates) were cotransfected, in a 1:1 molar ratio, with the vector 
plasmid (3 μg/plate) together with the helper/packaging plasmid pD1rs 
(10 μg/plate) expressing the AAV viral genes (rep gene from AAV serotype 
2 and cap gene from AAV serotype 1) and the adenoviral genes required for 
AAV replication and encapsidation (Plasmid Factory, Heidelberg, Germany). 
Fifty hours post-transfection, the medium was discarded and the cells were 
harvested by low-speed centrifugation and resuspended in Tris pH 8.0, NaCl 
0.1 M. After three cycles of freezing/thawing, the lysate was clarified by 30 
minutes centrifugation at 10,000 g, treated with benzonase (50 units/ml, 
Sigma) at 37 °C for 30 minutes, and centrifuged at 10,000 g for 30 minutes to 
eliminate the residual debris.
The virus was further purified by iodixanol gradient, QXL sepharose 
chromatography, buffer exchange, and microconcentration according to a 
 previously-described method.56
Viral genomes (vg) were titrated using quantitative polymerase 
chain reaction as previously described.57 Titers were 6.8 × 1011 vg/ml for 
 AAV2/1-V16-LUC, 2.3 × 1013 vg/ml for AAV2/1-V16-EGFP, 5.0 × 1012 vg/ml for 
AAV2/1-V16-GDNF, 8.9 × 1013 vg/ml for AAV2/1-M2-LUC and 1.4 × 1014 vg/ml 
for AAV2/1-M2-GDNF.
Infection of HEK 293T cells
Fifty thousand cells seeded in 48-well plates were incubated in the presence 
of rAAV2/1 at a multiplicity of infection of 103 vg/cell in serum-free medium 
containing human adenovirus 5 (H5) reference material (ATCC VR-1516; 
titer 5.8 × 1011 particle forming units (pfu)/ml) (LGC Standards, Teddington, 
Middlesex, UK) at the multiplicity of infection of 50 particle forming units 
(pfu)/cell. After 2 hours, the cells were rinsed with serum-supplemented 
medium and further cultured for 72 hours without passaging in culture 
medium containing or not Dox at the indicated concentration.
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GDNF ELISA
For determination of GDNF concentrations in rAAV-infected HEK-293T cells, 
the culture medium was harvested 72 hours postinfection.
For determination of GDNF brain tissue levels, animals were decapitated 
and the brains were removed, gradually frozen in isopentane/dry ice (−10 
°C for 10 seconds then −20 °C for 20 seconds) and stored at −80 °C. Two-
hundred-micrometer coronal slices were cut using a cryostat and striata 
were dissected out, weighed and processed for ELISA. For the preparation 
of the tissue extract, small pieces of striatum were triturated in T-per buffer 
(Pierce Fisher Scientific, Lucens, Switzerland) supplemented with protease 
inhibitors cocktail (Roche Diagnostics, Rotkreuz, Switzerland). Samples were 
centrifuged at 10,000×g and supernatants were harvested and their protein 
concentration analyzed using a nanodrop machine.
GDNF concentrations were measured using a commercial ELISA (Human 
GDNF CytoSets, catalog #CHC2423, BioSource, Nivelles, Belgium) and 
expressed in pictogram per milligram tissue. Recombinant human GDNF (pro-
vided by the manufacturer) was used to establish the standard curve.
In vitro luminometry
Seventy-two hours postinfection a volume of 50 µl of diluted passive-lysis 
buffer (Promega, Duebendorf, Switzerland, Cat.# E194A) was added to the 
HEK-293T cell monolayer. Plates were incubated for 30 minutes under shak-
ing at room temperature. The detached and lysed cells were harvested and 
centrifuged at 12,000g for 10 minutes. Twenty microliters of supernatant 
were loaded on a OptiplateTM-96 well, White Opaque 96-well Microplate 
(Perkin Elmer, Cat.# 6005290) for luciferase firefly activity measurements 
in the presence of luciferase assay substrate (Promega, Duebendorf, 
Switzerland, Cat. #. E1501) using a Mithras LB 940 Multilabel reader (Berthold 
Technologies, Zug, Switzerland).
Mice
Swiss CD1 mice purchased from Janvier Labs (Le Genest Ste Isle, France) 
were housed and treated according to the Belgian law. The protocols were in 
accordance with national rules on animal experiments and were approved 
by the Ethics Committee of the Faculty of Medicine of the ‘‘Universite´ 
Libre de Bruxelles’’. Animals were anesthetized with a mixture of ketamine 
(Imalgène 1000, Merial, Diegem, Belgium; 100 mg/kg) and xylazin (Rompun, 
Bayer, Diegem, Belgium; 10 mg/kg) and placed in a Kopf stereotaxic frame 
(Kopf Instruments, Tujunga, CA). The injection coordinates in the striatum 
were 0.8 mm anterior to the bregma, 1.5 mm lateral to the bregma (right 
side) and 3.5 mm (first site) and 2.5 mm (second site) below the dural sur-
face. At each injection site, 1 µl of viral suspension diluted in Dulbecco’s 
phosphate-buffered saline (Lonza, Verviers, Belgium) to the titer of 8.3 × 1010 
vg/ml. The injection rate was 0.2 μl/minute. The needle was left in place for 5 
minutes before a slow withdrawal over an additional minute.
When indicated, mice were fed with doxycycline-supplemented food 
(Dox diet, Safe, Augy, France) at the indicated dose. The food was replaced 
every second day in order to keep a stable Dox dose. Animals were then 
decapitated and the brains were rapidly dissected and frozen in methyl-
butane with dry-ice and then kept at −80 °C until use.
In vivo bioluminescence imaging
Mice were anesthetized with isoflurane (3%) vaporized in compressed air (3 
l/minute). Under anesthesia, the skin covering their skull was shaved using a 
hair shaver (Braun EP15) and hair-removal cream (Veet) the day before imag-
ing, and shaving was repeated when necessary during the study period.
Animals were injected intraperitoneally with 3 mg of luciferin (Promega, 
Leiden, The Netherlands) resuspended in 150 microliters of sterile saline 
(0.9% NaCl) and placed in the Photon Imager (Biospace Lab, France), where 
they were kept warm and anesthetized (1–1.5% isoflurane in compressed air 
(0.4 l/minute) delivered through a nose cone).
Animal experiments were in accordance with all institutional and national 
guidelines for the care and use of laboratory animals (LA 1500020, protocol 
MU/09/01).
Bioluminescent signal was collected using the Photo Acquisition software 
and quantified in cpm (counts per minute) 15 minutes after luciferin injec-
tion, by semi-automatic drawing of regions of interest using the M3 Vision 
software (both softwares were bundled with the Photon Imager).
Ex vivo luminometry (striatal extracts)
Striata were dissected from 100 µm thick cryostat brain sections. Striata 
pieces were kept in frozen microfuge tubes (−80 °C) until use. Tissue pieces 
were covered with 10 µl of ice cold Promega’s “Passive lysis buffer” per mg 
of striatum. Tissue was then mechanically disrupted by pumping the mix 
up and down twenty times on ice. The tubes were then centrifuged at max 
speed for 2 minutes at 4 °C and the supernatant was collected into a new 
microfuge tube.
Protein content of the extracts was quantified using the BCA kit (Thermo 
Scientific Life Technologies, Zug, Switzerland, Cat.# 23235) according to 
the manufacturer’s recommendations. Fifty microliters of protein extract 
of each sample were loaded on a Optiplate-96 well, White Opaque 
96-well Microplate (Perkin Elmer, Cat.# 6005290) for luciferase firefly activ-
ity measurements in the presence of luciferase assay substrate (Promega, 
Duebendorf, Switzerland, Cat. #. E1501) using a Mithras LB 940 Multilabel 
reader (Berthold Technologies, Zug, Switzerland).
Rats
For data in Figures  3, 4, 5, and 6a,c, the experiments were conducted 
on 38 female Wistar rats weighting approximately 200 g (7 weeks old) 
 (Janvier-Europe laboratories, France). All animal procedures were approved 
by the State Veterinary Office of Switzerland (authorization no. VD2759). 
Animals were housed in a 12-12 hour light–dark cycle room at 22 °C with free 
access to tap water and were fed ad libitum. They were anesthetized with 
a mixture of ketamine (75 mg/kg, Ketasol, Graeub AG, Basel, Switzerland) 
and xylazin (10 mg/kg, Rompun, Bayer, Zürich, Switzerland) and placed in 
a Kopf stereotaxic frame (Kopf Instruments). All rats underwent an injection 
of a viral suspension of rAAV2/1-V16-hGDNF (n = 32) or rAAV2/1-V16-EGFP 
(n = 6), diluted in Dulbecco’s phosphate-buffered saline at a titer 2.0 × 1012 
vg/ml at four delivery sites into the right striatum at the following coordi-
nates: (i) anterioposterior (AP) = + 0.0 mm, mediolateral (ML) = −3.6 mm, dor-
soventral (DV) = −4.0 and –5.0 mm and (ii) (AP) = + 1 mm, (ML) = −2.8 mm, 
dorsoventral (DV) = −4.5 and −5.5 mm, relative to the bregma and the dural 
surface. One µl of viral suspension was injected at each injection site at the 
rate of 0.2 µl/minute. After injection, the needle was left in place for 5 min-
utes in order to allow diffusion of the viral suspension in the parenchyma. 
When indicated, rats were fed with Dox-supplemented food (Dox diet) at 
the indicated dose. The food was replaced every two days in order to keep 
a stable Dox dose. At the end of the experiment, euthanasia was performed 
using pentobarbital injection at the dose of 300 mg/kg. When indicated, 
blood was harvested in heparinized tubes by intracardiac puncture under 
anesthesia. Animals were perfused transcardially with 100 ml of PBS pH 7.4 
followed by 200 ml of ice-cold 4% paraformaldehyde (PF4) in PBS pH 7.4. 
After overnight postfixation in PF4 at 4 °C, brains were transferred suces-
sively to sucrose 20 and 30% at 4 °C and stored at −80 °C.
For data in Figure 6b,d, 45 female Wistar rats weighing approx. 250 g were 
purchased from Janvier Labs (France) and were housed and treated accord-
ing to the Belgian law. The protocols were in accordance with national rules 
on animal experiments and were approved by the Ethics Committee of the 
Faculty of Medicine of the ‘‘Universite´ Libre de Bruxelles’’. Animals were anes-
thetized with a mixture of ketamine (Imalgène 1000, Merial, Diegem, Belgium; 
100 mg/kg) and xylazin (Rompun, Bayer, Diegem, Belgium; 10 mg/kg) and 
placed in a Kopf stereotaxic frame (Kopf Instruments). The injection in the 
striatum followed two injections tracks perpendicular to the skull surface: tra-
jectory 1: 0.2 mm anterior, 2.2 mm lateral to the bregma; trajectory 2: 0.2 mm 
anterior, 3.8 mm lateral to the bregma. Vector deposits were made at two dif-
ferent positions along those injection tracks at 4.5 and 6.0 mm below the dural 
surface. The needle was carefully lowered to the first level and left in place 5 
minutes before starting the injection. One microliter of vector was injected at 
each injection site at the rate of 0.2 µl/minute. At the end of the injection, the 
needle was left in place for 5 minutes before being slowly moved to the next 
injection coordinate.
When indicated, rats were fed with Dox-supplemented food (Dox diet, 
Safe, Augy, France) at the indicated dose. The food was replaced every sec-
ond day in order to keep a stable Dox dose.
When indicated, at the end of the experiment, blood was harvested in 
heparinized tubes by intracardiac puncture under anesthesia and animals 
were decapitated. Blood was centrifuged 10 minutes at 2,000 rpm and 
plasma was kept at −80 °C until use.
Bioassay of doxycycline concentrations in plasma
The Dox level in plasma samples was determined using a previously 
described cell-based assay.21 In brief, HeLaDOX cells were plated at a density 
of 104 cells per well in a 96-well plate in a total volume of 180 µl. After 24 
hours, 20 µl of diluted plasma sample was added to the cells. As a standard, 
cells were treated with 20 µl culture medium containing 0 to 100 ng/ml Dox. 
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After 48 hours, cells were washed with phosphate-buffered saline and lysed 
in passive lysis buffer (Promega, Leiden, The Netherlands). Firefly lucifer-
ase activity was determined using the Luciferase Assay System (Promega, 
Leiden, The Netherlands). The Dox concentration in the experimental sam-
ples was determined by extrapolation from the standard curve established 
in parallel.
Immunohistochemistry and quantification
For all immunostainings, 50 μm cryostat coronal sections were collected 
at 10 weeks post-vector injection. One of six brain sections were sequen-
tially incubated for 20 minutes in 3% H2O2 and 10% methanol in Tris 
buffer saline (10 mmol/l Tris, 0.9% NaCl; pH 7.6), incubated 1 hour in Tris 
buffer high salt triton (50 mmol/l Tris, 0.5 M NaCl, 0.5% Triton X-100; pH 
6) containing 5% bovine serum albumine and incubated overnight at 4 
°C with the primary antibody diluted in Tris buffer high salt triton con-
taining 1% bovine serum albumine. After washing, slices were incubated 
with a biotinylated secondary antibody during 1 hour at room tempera-
ture. The peroxidase staining was revealed with a VECTASTAIN Elite ABC 
kit and diaminobenzidine (Vector Laboratories, Burlingame, CA), accord-
ing to the manufacturer’s protocol. Sections were disposed on slides, 
dehydrated, and mounted with Eukitt mounting fluid (Sigma-Aldrich, 
VWR International, Nyon, Switzerland).
For GDNF immunostaining, a highly sensitive method was set up by per-
forming an additional step to a classical immunohistochemical labeling.31 
This step allowed retrieving antigen by heating brain slices for 10 minutes 
at 70 °C in sodium citrate buffer (10 mmol/l Na citrate, 0.05% tween 20, pH 
6). The primary incubation with a goat anti-GDNF antibody (1:500; R & D sys-
tems, Cat. #BAF212, Minneapolis, MN) was followed by an incubation with a 
biotinylated anti-goat antibody (1:500, Cat. #105605, Jackson Laboratories, 
PA). For TH immunostaining, the primary antibody was a mouse monoclo-
nal anti-TH (dilution 1:500, Cat. #MAB 318, Chemicon, Temecula, CA) and the 
secondary antibody was a biotinylated anti-mouse (1:400, Cat. #Bd553441, 
BD Pharmingen, BD Biosciences, Allschwil, Switzerland). For p-S6 staining, 
the primary antibody was a rabbit  anti-phospho-ribosomal protein S6 (Ser 
235 and 236) antibody (1:500, Cat. #2211, Cell signaling Technology, Beverly, 
MA) and the secondary antibody was a biotinylated goat anti-rabbit anti-
body (1:600, Cat. #BA1000, Vector Laboratories). For GFAP staining, a mouse 
anti-GFAP antibody (1:400, Cat. MAB360, Chemicon), followed by a biotinyl-
ated anti-mouse antibody (1:500, Cat. #553441, BD Pharmingen) were used. 
For Iba1 staining, a rabbit  anti-Iba1 antibody (1:20’000, Cat.019-19741, Wako 
Chemicals), followed by a biotinylated anti-rabbit antibody (1:400, Cat. #BA-
1000, Vector Laboratories) were used.
Images acquired using an Olympus BX40 microscope, at a 2-fold or 
20-fold magnification were saved as TIFF files using the Morpho Strider soft-
ware (Explora Nova, France).All the quantifications have been carried out at 
the twofold magnification using the mosaic function.TH and p-S6 biotinyl-
ated labeling optical densities quantification were respectively performed 
on four sections at the level of the injection and two to three sections at 
the level of SNc for each individual For GDNF staining, whole striatum was 
photographed. Surface quantifications were performed on 4 sections at the 
level of injection at a twofold magnification on each animal. Section surface, 
mean of grayscale and optical densities were quantified using ImageJ soft-
ware (NIH).
Amphetamine-induced rotation test
Rats were harnessed and connected to the automated rotameter bowls 
(Sandown Scientific, Hampton, UK). 2.5 mg/kg of D-amphetamine sulphate 
(Federa, Brussels, Belgium) was injected intraperitoneally. Right and left full 
body turns were recorded over 60 minutes. Mean net rotations are expressed 
as full body turns per 10 minutes ipsilateral minus contralateralto the lesion.
Statistical analysis
All the statistical analysis were performed using the GraphPad Software. 
Results were expressed as mean ± standard error of means. In vitro and in 
vivo comparison between M2 and V16 at increasing doses of doxycycline 
were analyzed using two-way analysis of variance followed by a Dunnett’s 
post-hoc analysis.
TH, p-S6 and GDNF immunostaining measurements were analysed using 
one-way analysis of variances followed by a Dunnett’s post-hoc analysis. 
Weight of rats and net turns performed on rotameter were analysed using 
a repeated measure one-way analysis of variance, followed by a Dunnett’s 
post-hoc test.
Differences were considered as significant when P < 0.05.
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